Values as of: 2024-05-24
COMMON STOCK | Medical Devices |
Last Closing
USD 208.04Change
-11.16 (-5.09)%Market Cap
USD 14.15BVolume
100.00Analyst Target
N/AVerdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 67.69B |
| SMMNY | Siemens Healthineers AG ADR |
N/A |
USD 67.09B |
| RYLPF | Koninklijke Philips N.V |
N/A |
USD 26.13B |
| SONVF | Sonova Holding AG |
N/A |
USD 19.66B |
| SONVY | Sonova Holding AG |
N/A |
USD 19.16B |
| CHEOY | CochLear Ltd ADR |
N/A |
USD 13.97B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 11.57B |
| WILYY | Demant A/S ADR |
N/A |
USD 10.38B |
| WILLF | Demant A/S |
N/A |
USD 10.35B |
| AMBFF | Ambu A/S |
N/A |
USD 5.73B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 4.81% | 65% | D | 57% | F | ||
| Dividend Return | 0.67% | 25% | F | 12% | F | ||
| Total Return | 5.48% | 65% | D | 56% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 26.65% | 80% | B- | 78% | C+ | ||
| Dividend Return | 1.52% | 33% | F | 19% | F | ||
| Total Return | 28.18% | 81% | B- | 77% | C+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 62.53% | 89% | A- | 82% | B | ||
| Dividend Return | 4.90% | 45% | F | 16% | F | ||
| Total Return | 67.43% | 88% | B+ | 81% | B- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 10.01% | 58% | F | 56% | F | ||
| Dividend Return | 10.81% | 60% | D- | 53% | F | ||
| Total Return | 0.80% | 50% | F | 19% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 22.27% | 92% | A | 83% | B | ||
| Risk Adjusted Return | 48.54% | 97% | N/A | 85% | B | ||
| Market Capitalization | 14.15B | 96% | N/A | 92% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
